FINAL Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore

First Page		Document Content
Date: 2016-07-21 12:08:20 Recombinant proteins Peptide hormones Generally Accepted Accounting Principles Biotechnology Eli Lilly and Company Insulin analog Biosimilar Biocon Trastuzumab Pharmaceutical industry in India Kiran Mazumdar-Shaw Biopharmaceutical		FINAL Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore Add to Reading List Source URL: www.biocon.com Download Document from Source Website File Size: 521,99 KB Share Document on Facebook

	FINAL Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore DocID: 1pawe - View Document
	OctoberINSULIN USE FOR TYPE 2 DIABETES MANAGEMENT WHAT INSULIN REGIMEN SHOULD DocID: 1fAJ9 - View Document
	humapen_luxura_vert_r_blk DocID: 17STq - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoLog® Mixsafely and effectively. See full prescribing information for NovoLog® Mix 70/30. ——— ADV DocID: 17Bn5 - View Document
	PDF Document DocID: 17c0f - View Document